Zacks Investment Research on MSN
Vertex Up 9.2% in 3 Months: Should You Buy, Sell or Hold the Stock?
Vertex Pharmaceuticals Incorporated VRTX stock has risen 9.2% in the past three months. However, the stock has significantly ...
Vertex Pharmaceuticals Incorporated VRTX reported second-quarter 2024 results on Aug 1. Adjusted loss per share of $12.83 was wider than the Zacks Consensus Estimate of a loss of $11.50. The ...
Vertex's cystic fibrosis portfolio has been a raging success for the company. The biotech’s next potential product addresses the extremely common problem of pain -- and could become its next ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback